Biohaven Pharmaceutical Holding Co Ltd. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash share-based compensation expense
Deferred interest on mandatorily redeemable preferred shares
Deferred interest on liability related to sale of future royalties
Non-cash interest expense
Fair value of contingent equity liability under license agreements
Fair value of warrants issued as consideration for license agreement
Deferred interest paid-in-kind on long-term debt
Issuance of common shares as payment for license and consulting agreements
Change in fair value of derivatives
Change in fair value of warrant liability
Change in fair value of contingent equity liability
Gain (loss) from equity method investment
Deferred tax assets
Depreciation and amortization
Change in obligation to perform R&D services
Other non-cash items
Changes in operating assets and liabilities:
Trade receivables, net
Inventories
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses and other current liabilities
Other long-term liabilities
Net cash used in operating activities

Cash flows from investing activities:
Purchase of marketable securities
Sales and maturities of marketable securities
Sales of marketable securities
Maturities of marketable securities
Total sales and maturities of marketable securities
Purchases of property and equipment
Purchase of equity method investment
Decrease in restricted cash
Payments for leasehold improvements
Payments for intangible assets
Net cash provided by (used in) investing activities

Cash flows from financing activities:
Proceeds from issuance of long-term debt
Proceeds from issuance of common shares
Proceeds from issuance of common shares upon completion of initial public offering, net of underwriting commissions and discounts
Proceeds from sale of future royalties
Proceeds from sale of contingently redeemable non-controlling interests
Proceeds from obligation to perform R&D services
Proceeds from issuance of common stock related to sale of future royalties
Proceeds from borrowings
Proceeds from issuance of mandatorily redeemable preferred shares
Proceeds from exercise of warrants
Payments of related party notes payable
Repayment of notes payable
Payments of debt issuance costs
Advanced payment for the second closing of Series A preferred stock
Payments of issuance costs and term loan commitment fee
Proceeds from exercise of share options and employee share purchase plan
Payments of principal for finance leases
Payments for term loan, finance leases and other
Net cash provided by financing activities

Cash at beginning of period
Cash at end of period
Effect of exchange rates on cash, cash equivalents and restricted cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income taxes
Deferred offering costs included in accounts payable and accrued expenses
Series A convertible preferred share offering costs included in accrued expenses
Issuance of warrants to guarantor and co-guarantor of notes payable
Beneficial conversion feature on Series A preferred shares
Issuance of Series A preferred shares as payment of offering costs
Issuance of Series A preferred shares in settlement of contingent equity liability
Issuance of common shares as payment of equity investment
Issuance of notes payable to related parties in connection with acquisition of BPI
Issuance of common share warrant as consideration for services
Exercise of stock options
Purchases of property and equipment included in accounts payable
Purchases of property and equipment under financing lease

Comments